According to a study, the overexpression of human epidermal growth factor 2 (HER2) in both cytology and surgical pathology specimens among patients with non-small cell lung cancer (NSCLC) can be used to identify those patients who would benefit from HER2-targeted therapies. These data were first presented by Olabisi Afolayan-Oloye, MD, MPH, Temple University Hospital, Philadelphia, Pennsylvania, at the 2025 College of American Pathologists Meeting (CAP25) in Orlando, Florida.
For the full article click here: Overexpression of HER2 Among Patients With Non-Small Cell Lung Cancer